Quarterly report pursuant to Section 13 or 15(d)

License and Collaboration Agreement (Details)

v3.22.1
License and Collaboration Agreement (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended
Aug. 17, 2021
Dec. 17, 2020
Dec. 31, 2020
Mar. 31, 2022
Mar. 31, 2021
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Research and development       $ 12,620 $ 9,833
Revenues       21,625 $ 914
License Agreement Terms | Otuska          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Upfront payments received   $ 50,000      
Potential regulatory milestone revenue   $ 50,000      
Revenues     $ 50,000 104  
License Agreement Terms | Otuska | Minimum          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Tiered royalty percentages on future sales   10.00%      
License Agreement Terms | Otuska | Maximum          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Tiered royalty percentages on future sales   20.00%      
License Agreement Terms | Riptide Bioscience, Inc.          
Research and Development Arrangement, Contract to Perform for Others [Line Items]          
Upfront license fee $ 6,000        
Research and development       $ 4,000